Table 3. Knowledge about the potential harms and benefits of tamoxifen by participant characteristics and univariable and multivariable logistic regression model (n=317).
| Good knowledge+ (%; N) | Univariable | Multivariable | |||
|---|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | ||
| Age | |||||
| ≤ 35 years | 10.3 (4) | 0.66 (0.20 – 2.11) | 0.479 | 0.54 (0.11 – 2.61) | 0.443 |
| 36 – 49 years | 16.9 (41) | 1.16 (0.61 – 2.21) | 0.644 | 0.71 (0.31 – 1.62) | 0.417 |
| ≥ 50 years | 14.9 (15) | Ref | Ref | ||
| Children | |||||
| Yes | 16.2 (48) | 1.21 (0.61 – 2.40) | 0.585 | 1.38 (0.54 – 3.56) | 0.504 |
| No | 13.8 (12) | Ref | Ref | ||
| Ethnic group * | |||||
| White | 15.1 (55) | - | - | - | - |
| Other | 28.6 (4) | - | - | - | - |
| Education level | |||||
| Degree or above | 22.2 (38) | 2.40 (1.36 – 4.25) | 0.003 | 2.24 (1.11 – 4.55) | 0.025 |
| Below degree level | 10.6 (22) | Ref | Ref | ||
| Health status | |||||
| Poor* | 20.0 (3) | - | - | ||
| Fair | 6.8 (5) | 0.36 (0.12 – 1.13) | 0.079 | 0.39 (0.11 – 1.41) | 0.149 |
| Good | 18.3 (42) | 1.12 (0.53 – 2.39) | 0.764 | 1.13 (0.48 – 2.65) | 0.777 |
| Excellent | 16.7 (10) | Ref | Ref | ||
| Risk level | |||||
| Moderate | 18.9 (43) | 1.82 (0.99 – 3.33) | 0.052 | 1.96 (0.95 – 4.04) | 0.069 |
| High | 11.3 (17) | Ref | Ref | ||
| Unclear* | 0.0 (0) | - | - | ||
| SES | |||||
| Low (most deprived) | 14.3 (16) | 0.83 (0.42 – 1.67) | 0.606 | 0.97 (0.43 – 2.22) | 0.945 |
| Middle | 15.0 (19) | 0.88 (0.45 – 1.71) | 0.704 | 0.87 (0.39 – 1.93) | 0.734 |
| High (least deprived) | 16.7 (23) | Ref | Ref | ||
| Employment | |||||
| Full-time | 16.1 (53) | Ref | Ref | ||
| All other employments | 13.0 (7) | 0.78 (0.33 – 1.81) | 0.556 | 1.07 (0.42 – 2.74) | 0.894 |
| Marital status | |||||
| Married or cohabiting | 16.3 (46) | 1.16 (0.60 – 2.21) | 0.662 | 0.99 (0.43 – 2.29) | 0.985 |
| Unmarried | 14.4 (14) | Ref | Ref | ||
| Numeracy | |||||
| Good numeracy | 19.0 (58) | 7.72 (1.84 – 32.43) | 0.005 | 5.91 (1.33 – 26.19) | 0.019 |
| Poor numeracy | 2.9 (2) | Ref | Ref | ||
| Received leaflet | |||||
| Yes | 17.9 (49) | 1.94 (0.97 – 3.89) | 0.062 | 1.54 (0.66 – 3.59) | 0.313 |
| No/unsure | 10.1 (11) | Ref | Ref | ||
| Satisfaction with HCP | |||||
| Mean ± SD | 19.34 ± 3.55 | 1.00 (0.93 – 1.09) | 0.922 | 0.98 (0.90 – 1.07) | 0.664 |
| Informed about tamoxifen | |||||
| Yes | 17.4 (58) | 4.85 (1.15 – 20.55) | 0.032 | 5.36 (0.67 – 42.66) | 0.113 |
| No | 4.2 (2) | Ref | Ref | ||
*
category not included in univariable and multivariable analyses due to insufficient cases. += This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and three potential harms of tamoxifen (increased risk of menopausal symptoms, blood clotting and endometrial cancer).